Introduction
Assertio Therapeutics (ASRT) is a specialty pharmaceuticals company which successfully divested itself of its painkiller exposure in response to the opioid crisis. Despite turnaround efforts such as a settlement with Purdue, cutting most of its sales force, and NDA for cosyntrophin, the company's is simply too indebted to grow its pipeline organically. While ASRT's core products are protected well into the mid-2020s from generic competition, they are no longer growing and it is unclear how the company can return to growth thereafter. Without further ado, let's take a look as to why.